Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...
The European Commission (EC) has approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, ...
"You could continue to work ad nauseum on all those issues, but at some point, patients need to take what they've learned in therapy out into the community. A therapist shouldn't foster lifelong ...